LY6G6D and colorectal carcinoma: To understand how ERKs and JAK/STAT5 signaling regulates CD15/FUT4 and LY6G6D function, we first investigated the treatment response of human CRC cells (N = 38) to the MEK inhibitor, Trametinib, and the JAK1/2 inhibitor, ruxolitinib, by integrating genomic and transcriptomic data from the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity from Cancer project, https://www.cancerrxgene.org/ (Fig. 4a and b).